open access

Vol 61, No 1 (2010)
Original papers
Published online: 2010-03-04
Submitted: 2013-02-15
Get Citation

Bone mineral density and metabolism in levothyroxine-treated adolescent girls with euthyroid diffuse goiter

Paweł Matusik, Ewa Małecka-Tendera, Edward Franek, Aleksandra Januszek-Trzciąkowska
Endokrynologia Polska 2010;61(1):14-19.

open access

Vol 61, No 1 (2010)
Original papers
Published online: 2010-03-04
Submitted: 2013-02-15

Abstract


Introduction: Bone and mineral metabolism is influenced by thyroid hormones, and levothyroxine (LT4) therapy may be associated with reduced bone mass in postmenopausal women.
Material and methods: The aim of the study was to assess the influence of one year of LT4 treatment in a group of 21 adolescent girls with euthyroid diffuse goiter. Lumbar (L2-L4) and total body bone mineral density (TOBMD) (Lunar - DXA), serum PTH, osteocalcin, bone alkaline phosphate, vitamin D3, calcium, and phosphorus levels and urinary excretion of Ca, P, and hydroxyproline were measured before and after one year of combined LT4 and iodine treatment.
Results: Patients were matched for age, sex, BMI, and maturation status, with controls treated with iodine only. Markers of bone turnover changed in a similar manner in both groups. There was no significant difference in TOBMD value after one year of therapy between LT4 treated group and controls. Densitometric lumbar spine parameters increased significantly after 12 months in both groups, with no significant differences between them.
Conclusion: It can be concluded that one year of LT4 treatment of adolescent girls with euthyroid diffuse goiter does not have a negative impact on their bone remodelling and metabolism.
(Pol J Endocrinol 2010; 61 (1): 14-19)

Abstract


Introduction: Bone and mineral metabolism is influenced by thyroid hormones, and levothyroxine (LT4) therapy may be associated with reduced bone mass in postmenopausal women.
Material and methods: The aim of the study was to assess the influence of one year of LT4 treatment in a group of 21 adolescent girls with euthyroid diffuse goiter. Lumbar (L2-L4) and total body bone mineral density (TOBMD) (Lunar - DXA), serum PTH, osteocalcin, bone alkaline phosphate, vitamin D3, calcium, and phosphorus levels and urinary excretion of Ca, P, and hydroxyproline were measured before and after one year of combined LT4 and iodine treatment.
Results: Patients were matched for age, sex, BMI, and maturation status, with controls treated with iodine only. Markers of bone turnover changed in a similar manner in both groups. There was no significant difference in TOBMD value after one year of therapy between LT4 treated group and controls. Densitometric lumbar spine parameters increased significantly after 12 months in both groups, with no significant differences between them.
Conclusion: It can be concluded that one year of LT4 treatment of adolescent girls with euthyroid diffuse goiter does not have a negative impact on their bone remodelling and metabolism.
(Pol J Endocrinol 2010; 61 (1): 14-19)
Get Citation

Keywords

euthyroid diffuse goiter; children; levothyroxine; bone mineral density; bone turnover markers

About this article
Title

Bone mineral density and metabolism in levothyroxine-treated adolescent girls with euthyroid diffuse goiter

Journal

Endokrynologia Polska

Issue

Vol 61, No 1 (2010)

Pages

14-19

Published online

2010-03-04

Bibliographic record

Endokrynologia Polska 2010;61(1):14-19.

Keywords

euthyroid diffuse goiter
children
levothyroxine
bone mineral density
bone turnover markers

Authors

Paweł Matusik
Ewa Małecka-Tendera
Edward Franek
Aleksandra Januszek-Trzciąkowska

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl